Prostate Cancer Diagnostics And Therapy Market Share

Statistics for the 2023 & 2024 Prostate Cancer Diagnostics And Therapy market share, created by Mordor Intelligence™ Industry Reports. Prostate Cancer Diagnostics And Therapy share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Prostate Cancer Diagnostics And Therapy Industry

The market for prostate cancer diagnostics and therapy is highly competitive due to the presence of a number of market players. Several large drug and equipment manufacturers exist within the global prostate cancer diagnostic and therapy market, and their status as major players lies primarily within specific product markets. Some of the key players in the market include Abbott Laboratories, Astellas Inc., AstraZeneca, Bayer HealthCare AG, Cellanyx Diagnostics Inc., Dendreon Corporation, Ferring Pharmaceuticals, Ipsen Group, Sanofi-Aventis, Tolmar Inc, GE Healthcare, Siemens Healthineers, and F. Hoffmann-La Roche AG. 

Prostate Cancer Diagnostics & Therapy Market Leaders

  1. Bayer AG

  2. AstraZeneca PLC

  3. Sanofi-Aventis

  4. Thermo Fisher Scientific

  5. F. Hoffmann-La Roche Ltd.

*Disclaimer: Major Players sorted in no particular order

Prostate Cancer Diagnostics and Therapy Market Concentration

Prostate Cancer Diagnostics and Therapy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)